Campylobacter
Vaccines Forecast
Campylobacter jejuni remains the world's most common cause of bacterial gastroenteritis, driving an estimated 96 million infections a year and around 41,000 deaths among children under five in endemic countries, while also triggering Guillain-Barre syndrome in roughly one in 1,000 cases. More than half of retail Campylobacter isolates are now fluoroquinolone-resistant, and WHO lists the pathogen among those most urgently needing new antibiotics. Against that backdrop, CJCV2 has reported the field's first published Phase 1 human trial data for a Campylobacter conjugate vaccine. This is a comprehensive, wide geography commercial assessment of the Campylobacter vaccine opportunity, drawing on VacZine Analytics' long standing, independent authority in endemic and diarrhoeal disease vaccine markets.
- Format
- PDF (~150 slides) + Excel model
- Markets modelled
- Endemic (47 countries), traveler & military
- Scenarios
- LO / BASE / HI pricing
- Forecast horizon
- To 2035
- Approach
- Value/volume demand model
- Base edition
- 2020
- Availability
- Syndicated / bespoke
infections worldwide each year
five attributed to Campylobacter
now fluoroquinolone-resistant
available today
A far larger burden than once estimated, and a resistance problem that keeps widening
This review sets out the current disease background, global burden and R&D competitive landscape for Campylobacter jejuni, drawing on the latest WHO/FERG and antimicrobial resistance surveillance data.
Pathogen overview - Campylobacter jejuni
Campylobacter jejuni is a major cause of gastroenteritis worldwide and is also associated with Guillain-Barre syndrome (GBS) and other post-infectious complications. Gastroenteritis typically develops 24 to 72 hours after ingestion, most often from undercooked poultry or contaminated water, and manifests as acute watery or bloody diarrhoea, fever, weight loss and cramps lasting around six days. Campylobacteriosis is the sixth most common known cause of diarrhoeal death in children aged under five and remains the most common cause of bacterial gastroenteritis worldwide; it also affects Western travellers to endemic countries and has long been a recognised cause of illness among deployed military personnel. When VacZine Analytics last published on this market in 2020, the field's headline burden estimate stood at 7.5 million DALYs, based on 2010 data.
That estimate has since been superseded by considerably larger figures as surveillance and modelling methods have improved. WHO's Foodborne Disease Burden Epidemiology Reference Group attributes approximately 96 million Campylobacter infections to foodborne and other transmission routes each year, making it the second-leading cause of foodborne illness worldwide after norovirus. Among children aged five and under, Campylobacter-attributed diarrhoea causes an estimated 88 million episodes and around 41,000 deaths annually, with the heaviest burden concentrated in low- and middle-income countries. In roughly one in every 1,000 infections, C. jejuni triggers Guillain-Barre syndrome, an autoimmune neurological disease caused by molecular mimicry between bacterial and human nerve-cell surface molecules, adding a serious, if infrequent, complication to an already substantial diarrhoeal disease burden.
Antimicrobial resistance has continued to erode treatment options. WHO classifies fluoroquinolone- and macrolide-resistant Campylobacter among its high-priority pathogens for new antibiotic development, and recent global surveillance shows more than half of retail-level Campylobacter isolates are now fluoroquinolone-resistant, with rates as high as 79% in South and Central America, 74% in North Africa, 87% in China and 89% in Thailand, against lower rates in North America (15%) and Oceania (11%). Fluoroquinolone resistance has roughly doubled over the past two decades, driven substantially by antibiotic use in livestock and poultry production, the principal source of around 80% of human cases. Against that backdrop, the field has reported its first published human trial data for a Campylobacter conjugate vaccine: CJCV2, an NIH-funded candidate, completed a randomised, double-blinded Phase 1 trial at Cincinnati Children's Hospital Medical Center between 2022 and 2024, testing three doses in around 60 healthy adults with and without the Army Liposome Formulation adjuvant containing QS-21 (ALFQ). The vaccine was well tolerated, with adverse effects mostly limited to injection-site symptoms, and produced measurable antibody responses, with the strongest immune response recorded at a lower dose, encouraging news for a future multivalent product covering multiple C. jejuni strains.
A first published human trial, against a resistance problem that keeps widening
After decades without a Campylobacter vaccine candidate reaching human testing, CJCV2's Phase 1 readout marks the field's first published clinical data, arriving as fluoroquinolone resistance climbs across every major surveillance region.
-
NIH-funded consortium / Cincinnati Children's HospitalPhase 1 complete (2022-2024)CJCV2 (Campylobacter jejuni Conjugate Vaccine) Capsule polysaccharide conjugate, ± ALFQ adjuvant
A randomised, double-blinded Phase 1 trial in around 60 healthy adults tested three doses with and without the Army Liposome Formulation adjuvant containing QS-21 (ALFQ); the vaccine was safe and immunogenic, with the strongest antibody response at a lower dose. -
US Army / academic research groupsPreclinical / early-stageEnterobactin & outer-membrane protein conjugates
Iron-scavenging and outer-membrane-protein-targeted candidates continue in earlier-stage development, building on decades of capsule polysaccharide and glycoconjugate research first flagged in the original 2020 MarketVIEW edition. -
Poultry-sector interventionsPre-harvest control programmesOn-farm & pre-harvest reduction strategies
Vaccination and biosecurity interventions targeting poultry, the source of around 80% of human cases, remain a complementary route to reducing exposure ahead of any licensed human vaccine. -
WHO / national surveillance networksActive AMR surveillanceGlobal Campylobacter resistance monitoring
Ongoing tracking of fluoroquinolone- and macrolide-resistant Campylobacter, both WHO high-priority pathogens, continues to inform treatment guidelines and vaccine target product profile design.
CJCV2's randomised Phase 1 trial is the first published human clinical data for a Campylobacter vaccine candidate in the vaccine's decades-long development history, arriving just as fluoroquinolone resistance among retail Campylobacter isolates has passed 50% in several major surveillance regions. That combination, genuine first clinical proof against a hardening resistance problem, reframes the commercial case across endemic paediatric, traveler and military market segments alike. The VacZine Analytics model quantifies this opportunity under LO/BASE/HI pricing scenarios reflecting successive targeting of the 47 endemic countries covered, ranked by DALYs per WHO region.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, current R&D status and scenario-based demand forecasting across endemic, traveler and military markets to 2035.
Value ($m) and volume (million doses) forecasts to 2035 across 47 endemic countries, Western traveler segments and a US military market estimate.
Full review of CJCV2's Phase 1 data and the wider Campylobacter conjugate and subunit R&D landscape.
Target product profile, launch timeframe assumptions, pricing and market penetration estimates for endemic, traveler and military segments.
Three pricing-justified revenue scenarios based on successive targeting of endemic countries ranked by DALYs per WHO region.
Global case, death and Guillain-Barre syndrome complication data updated through WHO/FERG's most recent reporting.
Assessment of rising fluoroquinolone and macrolide resistance and its implications for treatment guidelines, vaccine TPP and market access.
A glimpse of the commercial model
The table below shows a partial view of the market-segment and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Market segment | Geography | Sector | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Endemic - children in 47 target countries | Africa, Asia, Americas | Public/private | Pre-licensure | Modelled |
| Traveler - Western points of origin | US, EU & ROW source markets | Private | Pre-licensure | Modelled |
| US military market | Global deployment regions | Public | Pre-licensure | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All sectors | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the Campylobacter vaccine opportunity across endemic, traveler and military markets.
- Executive presentation (~150 slides, PDF) - disease background, epidemiology, R&D status and full commercial assessment with supporting narrative and references
- MS-Excel forecast model - value ($m) and volume (million doses) predictions to 2035 across endemic, traveler and military market segments
- LO/BASE/HI pricing scenarios - three forecast scenarios based on successive targeting of 47 endemic countries ranked by DALYs per WHO region
- Competitor intelligence - CJCV2's Phase 1 data and the wider Campylobacter conjugate and subunit R&D landscape
- Updated epidemiology module - WHO/FERG 2025-2026 update covering global burden, under-5 mortality, Guillain-Barre syndrome risk and antimicrobial resistance trends
- TPP, launch timing & penetration estimates - target product profile, launch timeframe and pricing/penetration assumptions for endemic, traveler and military segments
Built for organisations weighing the Campylobacter vaccine opportunity
Most valuable to teams evaluating the Campylobacter vaccine market against their own pipeline, BD ambitions or investment thesis, now that a conjugate candidate has cleared human trials.
Vaccine developers
Positioning and commercial feasibility assessment for Campylobacter candidates at any stage, informed by CJCV2's first published Phase 1 data.
Corporate strategy & BD
Validate the size and structure of a still-open market with no incumbent vaccine, now that a conjugate candidate has cleared human trials.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on NIH-funded programmes and future Campylobacter entrants.
Public health & travel medicine bodies
Demand modelling and country-level risk classification to support endemic, traveler and military Campylobacter vaccine planning.
Researchers & academia
Comprehensive epidemiology, antimicrobial resistance and Guillain-Barre syndrome research landscape for grant and translational planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across endemic, traveler and military channels worldwide.
VacZine Analytics has tracked endemic and diarrhoeal disease vaccine markets since our earliest editions, positioning us to reassess the Campylobacter vaccine opportunity the moment the field's leading candidate reported its first published human trial data. This is a genuinely comprehensive analysis with a wide geographic focus spanning 47 endemic countries alongside traveler and military market segments, and it has been well received by clients across the field for the depth of its epidemiology and DALY-based country-targeting model. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.
This 2020 edition has been further refreshed to incorporate WHO/FERG's most recent burden estimates, updating the field's headline figure from 7.5 million DALYs (2010 data) to approximately 96 million annual infections and 41,000 under-five deaths, alongside CJCV2's Phase 1 trial results and the accelerating spread of fluoroquinolone-resistant Campylobacter. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Campylobacter analysis, a briefing call is included on request.